Patients with advanced , unresectable NETs of pancreatic , gastrointestinal foregut or unknown primary site were randomised to receive three-weekly capecitabine ( Cap ) 625 mg/m ( 2 ) twice daily orally , streptozocin ( Strep ) 1.0 g/m ( 2 ) intravenously on day 1 , with or without cisplatin ( Cis ) 70 mg/m ( 2 ) intravenously on day 1 .